

タイトル	Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: A prospective study of initial 6 month follow up
別タイトル	前立腺癌患者におけるアンドロゲン除去療法施行時の動脈硬化ならびに血清脂質変化に与える影響についての初期6ヶ月前向き研究
作成者（著者）	岡, 了
公開者	東邦大学
発行日	2016.03
掲載情報	東邦大学大学院医学研究科 博士論文. 15.
資料種別	学位論文
内容記述	主査：中島耕一 / タイトル：Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: A prospective study of initial 6 month follow up / 著者：Ryo Oka, Takanobu Utsumi, Takumi Endo, Masashi Yano, Shuichi Kamijima, Naoto Kamiya, Kohji Shirai, Hiroyoshi Suzuki / 掲載誌：International Journal of Clinical Oncology / 巻号・発行年等：21(2):389-396, 2016 / 本文ファイル: 査読後原稿 / The original publication is available at www.springerlink.com
著者版フラグ	ETD
報告番号	32661甲第788号
学位授与年月日	2016.3.29
学位授与機関	東邦大学
DOI	info:doi/10.1007/s10147-015-0891-7
その他資源識別子	http://link.springer.com/article/10.1007%2Fs10147-015-0891-7
メタデータのURL	https://mylibrary.toho-u.ac.jp/webopac/TD50437484

1
2
3 **Original article**
4
5
6
7
8

9 **Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile**
10
11
12 **changes in patients with prostate cancer: a prospective study of initial 6-month**
13
14
15
16 **follow-up**
17
18
19
20
21

22 Ryo Oka¹), Takanobu Utsumi¹), Takumi Endo¹), Masashi Yano¹), Shuichi Kamijima¹),
23

24 Naoto Kamiya¹), Kohji Shirai²), Hiroyoshi Suzuki¹)
25
26
27
28
29
30
31
32
33

34 1) Department of Urology, Toho University Sakura Medical Center, Sakura, Japan
35

36
37 564-1 Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan
38
39

40 2) Seijinkai-Mihama Hospital, Chiba, Japan
41
42

43 1-1-5 Utase, Mihama-ku, Chiba-shi, Chiba, 261-0013, Japan
44
45
46
47
48

49 **Author to whom correspondence should be addressed:** Takanobu Utsumi, MD, PhD
50

51 Department of Urology, Toho University Sakura Medical Center, Sakura, Japan
52

53 564-1 Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan
54
55

56 Tel: +81-43-462-8811; Fax: +81-43-462-1700
57

58
59 E-mail: takanobu.utsumi@med.toho-u.ac.jp
60
61
62
63
64
65

1
2
3
4
5 **Key words:** androgen deprivation therapy, arterial stiffness, cardio-ankle vascular index,
6
7 high density-lipoprotein cholesterol, low density-lipoprotein cholesterol, prostate cancer
8
9

10
11
12 **Short title:** Arterial stiffness in androgen deprivation therapy
13
14
15

16
17 **Funding statement:** This work was supported by a Grant-in-Aid for Scientific
18
19 Research (C) from the Ministry of Education, Science, Sports and Culture of Japan (No.
20
21 25462503) to Hiroyoshi Suzuki.
22
23
24
25
26

27 **Abstract word count:** 231 words
28
29
30

31 **Text word count:** 2849 words
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Background

To explore arterial stiffness monitored with a new indicator, the cardio-ankle vascular index (CAVI), and serum lipid profile changes during the administration of androgen deprivation therapy (ADT) in patients with prostate cancer (PCa).

Methods

A prospective study assessed the changes of arterial stiffness using CAVI and clinical laboratory variables among 58 men with prostate cancer treated with ADT for 6 months. Furthermore, patients who had a high risk of developing arterial stiffness after ADT were investigated.

Results

The whole cohort had no significant increase in arterial stiffness within 6 months after ADT, but 55.2% of patients had increased CAVI. Serum levels of total cholesterol, high density lipoprotein-cholesterol (HDL-C), and low density lipoprotein-cholesterol (LDL-C) increased significantly at 1 month after the start of ADT and sustained the high values. At baseline HDL-C was lower and LDL-C and LDL-C/HDL-C was higher in the group with than without an increased CAVI after 6 months of ADT administration.

Conclusions

1
2
3 Although the whole cohort did not show a significant change in arterial stiffness with
4
5
6 ADT, some patients showed an increased arterial stiffness monitored with the CAVI.
7

8
9 The balance between HDL-C and LDL-C, or HDL-C/LDL-C, might have an impact on
10
11 the development of arterial stiffness after ADT administration. Thus, clinicians might be
12
13 able to monitor PCa patients who have a high risk of development of arterial stiffness
14
15
16
17
18
19 after ADT administration by referring to LDL-C/HDL-C levels.
20

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

INTRODUCTION

Prostate cancer (PCa) is one of the most common cancers affecting men in Western countries, and its incidence in Japan is rapidly increasing.^{1,2} The overall 5-year survival of all patients with PCa is very favorable.^{3,4} Because of the high survival rate of patients with this cancer, consideration of mortality related to chronic treatment has become important. In recent years, androgen deprivation therapy (ADT) has been increasingly used in PCa patients.⁵ The role of ADT in the treatment of PCa has been extended from being used predominantly in symptomatic metastatic disease to asymptomatic metastatic disease, primary therapy in localized disease when men are considered unfit for surgery or radiotherapy, adjunct treatment in high-risk disease treated with radiotherapy, and salvage therapy following a biochemical relapse after surgery or radiotherapy for presumed localized disease.^{6, 7}

ADT can be accomplished with a gonadotropin-releasing hormone (GnRH) agonist, a GnRH antagonist, or bilateral orchiectomy. Anti-androgen drugs can also be used with GnRH agonists to produce combined androgen blockade. However, as a result of ADT, the profound testosterone deficiency is associated with a range of potential adverse short- and long-term consequences affecting physical and psychological health, including hot flushes, sexual dysfunction, obesity, sarcopenia, dyslipidemia,

1
2
3 hyperinsulinemia, osteoporosis, type 2 diabetes mellitus (DM), and cardiovascular
4
5
6 disease (CVD).⁵⁻⁷ In particular, CVD and the many adverse cardio-metabolic effects
7
8
9 caused by ADT may negatively impact the overall health of PCa survivors.⁶
10

11
12 Arterial stiffness is a useful surrogate marker for CVD. It is based on the structural
13
14 changes occurring prior to plaque or thrombus formation in muscular and elastic vessels.
15
16

17
18
19 ^{8,9} Although pulse wave velocity (PWV) has been designed to assess arterial stiffness as
20
21 a general method, it is known to depend on blood pressure (BP) at the time of
22
23 measurement. Hence, the cardio-ankle vascular index (CAVI) was subsequently
24
25 developed to obtain a more accurate arterial stiffness index that is not affected by BP at
26
27 the time of measurement.^{8,9} The CAVI showed high values in aging, CVD, chronic
28
29 kidney disease, and cerebral infarction.¹⁰ Furthermore, patients with CVD risk factors,
30
31 such as hypertension, DM, dyslipidemia, and obesity, also showed high values.¹¹
32
33
34
35
36
37
38
39
40

41 The strong relationship between the serum lipid profile and the incidence of CVD is
42
43 well established. Low-density lipoprotein cholesterol (LDL-C) is the main parameter for
44
45 some risk assessment tools of CVD.¹² Another alternative parameter is the ratio of
46
47 LDL-C to high-density lipoprotein cholesterol (HDL-C) (LDL-C/HDL-C), which has
48
49
50
51 been reported to be strongly associated with CVD and is thought to be a better predictor
52
53
54
55
56
57 of future CVD than LDL-C.¹²
58
59
60
61
62
63
64
65

1
2
3 Given the close association between arterial stiffness and CVD, it is crucial to
4
5
6 determine whether ADT increases the likelihood of arterial stiffness. Therefore, the
7
8
9 effects of short-term ADT on arterial stiffness changes were investigated using the
10
11
12 CAVI in patients with PCa. In addition, the effects of ADT on the serum lipid profile,
13
14
15 including LDL-C/HDL-C, were investigated, because of the close relationships among
16
17
18 arterial stiffness, CVD, and dyslipidemia.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

PATIENTS AND METHODS

Study participants and design

This was a prospective observational study approved by the institutional review board of Toho University Sakura Medical Center (No. 2012-008). Patients' personal data were treated with strict confidentiality. All patients gave their written, informed consent.

A total of 65 patients with pathologically confirmed PCa scheduled to receive ADT for more than 6 months were seen in our institution between March 2012 and December 2014. Seven patients were excluded from the present study because of other cancer deaths, lost to follow-up, or missing values at 6 months after the start of ADT. Finally, the data of 58 patients were statistically analyzed in the present study. All patients had Eastern Cooperative Oncology Group performance status of 0-1. Table 1 shows the demographic and baseline characteristics of the patients included in the final analysis.

Indications for ADT in this study were the following: 35 patients as primary treatment, 18 patients as combination with radiotherapy, and 5 patients due to biochemical recurrence after radical prostatectomy. The following agents were used as ADT at the discretion of each urologist. Thirty-two patients received goserelin subcutaneously in combination with oral bicalutamide 80 mg daily. Twenty-one patients received leuporelin subcutaneously in combination with oral bicalutamide 80 mg daily. Five

1
2
3 patients received only degarelix subcutaneously.
4
5

6 The following clinical data were assessed at baseline (Table 1): age, body mass index,
7
8
9 systolic and diastolic BP, pulse pressure, HbA1c, and comorbidities. Moreover, the
10
11
12 following clinical data were assessed and compared at baseline and after 1 month, 3
13
14
15 months, and 6 months of follow-up (Figure 1): prostate-specific antigen (PSA),
16
17
18 testosterone, estimated glomerular filtration rate (eGFR), triglycerides, total cholesterol
19
20
21 (TC), HDL-C, LDL-C, LDL-C/HDL-C, C-reactive protein (CRP), diacron-reactive
22
23
24 oxygen metabolites (d-ROMs), and the CAVI.
25
26

27 28 **Measurement of the CAVI**

29
30
31 The CAVI was measured with a VaSera CAVI instrument (Fukuda Denshi Co Ltd,
32
33
34 Tokyo, Japan) by the method described previously.⁸ Briefly, cuffs were applied to
35
36
37 bilateral upper arms and ankles, with the subject lying supine and the head held in the
38
39
40 midline position. After resting for 10 minutes, the examinations were performed. To
41
42
43 detect the brachial and ankle pulse waves with cuffs, a low cuff pressure from 30 to 50
44
45
46 mmHg was used to minimize the effect of cuff pressure on hemodynamics. BP was then
47
48
49 measured. Finally, to compare with PWV results, scale conversion was performed. The
50
51
52 CAVI was calculated using the following formula: $CAVI = a\{(2p/\Delta P) \times$
53
54
55 $\ln(Ps/Pd)PWV^2\} + b$, where Ps is systolic BP, Pd is diastolic BP, PWV is pulse wave
56
57
58
59
60
61
62
63
64
65

1
2
3 velocity, ΔP is $P_s - P_d$, ρ is blood density, and a and b are constants. BP values were
4
5
6 obtained using the cuff applied to the upper arm. PWV was obtained by dividing the
7
8
9 length of the blood vessel by the time taken for the pulse wave to propagate from the
10
11
12 aortic valve to the ankle, and it was measured using the cuffs attached to the upper arms
13
14
15 and ankles. To be compatible with the aortic PWV method established by Hasegawa
16
17
18 and coworkers,¹³ scale conversion constants (a , b) were determined so as to match the
19
20
21 CAVI with the aortic PWV method. Using the scale conversion constants, the CAVI
22
23
24 data obtained can be compared with the massive amount of previous data of PWV. All
25
26
27 the measurement and calculation functions are integrated in the VaSera CAVI
28
29
30 instrument that automatically calculates and generates the final data. The average
31
32
33 coefficient of variation of the CAVI is less than 5%, which is small enough for clinical
34
35
36 usage and indicates that the CAVI has good reproducibility.¹⁴ Furthermore, the CAVI is
37
38
39 a patient-friendly method of assessing arterial stiffness in daily clinical practice, because
40
41
42 it can show age-reference intervals in healthy persons.
43
44
45
46

47 **Statistical analysis**

48
49
50 The results are reported as means (\pm standard deviation). First, the CAVI was
51
52
53 evaluated at baseline using t -tests or Mann-Whitney U tests for the categorical variables
54
55
56 and correlation analyses for the continuous variables. Second, the changes in the clinical
57
58
59
60
61
62
63
64
65

1
2
3 laboratory variables were compared in all patients using the paired t -test or the
4
5
6 Wilcoxon signed-rank test between baseline, and 1 month, 3 months, and 6 months of
7
8
9 follow-up. Third, the patients were divided into two groups according to whether the
10
11
12 CAVI increased at 6 months of follow-up. In each group of patients, the changes in the
13
14
15 clinical laboratory variables were compared using the paired t -test or the Wilcoxon
16
17
18 signed-rank test between baseline and 6 months of follow-up. Last, univariate analyses
19
20
21 were performed to evaluate the association between increased CAVI and baseline
22
23
24 variables using t -test or Mann-Whitney U test for continuous variables and χ^2 test for
25
26
27 categorical variables. Statistical significance was defined as $P < 0.050$. All statistical
28
29
30 analyses were performed using SPSS Statistics 22 (IBM company, Chicago, IL, USA).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

RESULTS

At baseline, the CAVI was significantly higher in patients with hypertension (9.3 [\pm 0.9] versus 8.6 [\pm 1.0], $P=0.005$) and DM (9.5 [\pm 0.7] versus 8.8 [\pm 1.1], $P=0.009$). It was also higher in patients with dyslipidemia (9.1 [\pm 0.9] versus 8.9 [\pm 1.0], $P=0.262$) and CVD (9.3 [\pm 0.9] versus 8.9 [\pm 1.0], $P=0.112$). Moreover, the CAVI was significantly correlated with age ($r=0.373$, $P=0.004$), pulse pressure ($r=0.367$, $P=0.005$), and HbA1c ($r=0.297$, $P=0.026$). The following clinical variables at baseline were not significantly correlated with CAVI: BMI ($r=0.103$, $P=0.443$), systolic BP ($r=0.233$, $P=0.079$), diastolic BP ($r=-0.019$, $P=0.890$), PSA ($r=-0.115$, $P=0.391$), testosterone ($r=-0.137$, $P=0.307$), eGFR ($r=-0.073$, $P=0.588$), triglycerides ($r=0.102$, $P=0.444$), total cholesterol ($r=-0.042$, $P=0.753$), HDL-C ($r=0.116$, $P=0.385$), LDL-C ($r=-0.133$, $P=0.321$), LDL-C/HDL-C ($r=-0.124$, $P=0.307$), d-ROMs ($r=-0.023$, $P=0.869$), and CRP ($r=0.131$, $P=0.326$).

Figure 1 shows the changes as a whole in the following clinical laboratory variables at baseline, 1 month, 3 months, and 6 months of follow-up: PSA, testosterone, eGFR, triglycerides, TC, HDL-C, LDL-C, LDL-C/HDL-C, CRP, d-ROMs, and the CAVI. ADT significantly lowered serum testosterone levels to castration level in all patients ($P<0.001$). It also significantly lowered PSA ($P<0.001$) (Figure 1a and 1b). After 1 month

1
2
3 of follow-up, TC, HDL-C, and LDL-C increased significantly from 185.5 [\pm 34.1]
4
5
6 mg/dL to 206.2 [\pm 33.6] mg/dL ($P < 0.001$), from 51.2 [\pm 11.3] mg/dL to 59.0 [\pm 15.0]
7
8
9 mg/dL ($P < 0.001$), and from 108.1 [\pm 31.3] mg/dL to 119.2 [\pm 32.9] mg/dL ($P < 0.001$),
10
11
12 respectively (Figure 1e, 1f, and 1g). On the other hand, after ADT administration, no
13
14
15 significant changes were observed in the following variables: eGFR (from 67.3 [\pm 14.3]
16
17
18 mL/min/1.73 m² to 66.2 [\pm 13.9] mL/min/1.73 m², $P = 0.230$), triglycerides (from 147.7
19
20
21 [\pm 77.5] mg/dL to 160.7 [\pm 113.9] mg/dL, $P = 0.521$), LDL-C/HDL-C (from 2.2 [\pm 0.8] to
22
23
24 2.2 [\pm 0.9], $P = 0.294$), CRP (from 0.13 [\pm 0.28] mg/dL to 0.09 [\pm 0.21] mg/dL, $P = 0.301$),
25
26
27 d-ROMs (from 341.1 [\pm 63.8] U.CARR to 336.9 [\pm 73.3] U.CARR, $P = 0.564$), and the
28
29
30 CAVI (from 9.0 [\pm 1.0] to 9.0 [\pm 1.2], $P = 0.585$) (Figure 1c, 1d, 1h, 1i, 1j, and 1k).
31
32
33
34 Moreover, TC, HDL-C, and LDL-C were significantly higher at 3 months and 6 months
35
36
37 of follow-up, as compared to their baseline values. CRP gradually decreased and was
38
39
40 significantly lower at 6 months of follow-up as compared to the baseline value. The
41
42
43 other variables did not show significant changes at 3 months and 6 months of follow-up
44
45
46 as compared with their baseline values.
47
48
49

50
51 Although the CAVI in the whole cohort did not show a significant change after the
52
53
54 start of ADT, the CAVI increased in 32 patients at 6 months of follow-up. Table 2 shows
55
56
57 the changes in clinical laboratory variables from baseline to 6 months of follow-up, after
58
59
60
61
62
63
64
65

1
2
3 patients were divided into two groups according to whether the CAVI increased at 6
4
5
6 months of follow-up. HDL-C and LDL-C increased significantly in both groups, while
7
8
9 LDL-C/HDL-C did not increase significantly in both groups (Table 2). Table 3 shows
10
11 univariate analyses of the clinical variables at baseline for increased arterial stiffness
12
13 after ADT. HDL-C was lower and LDL-C/HDL-C was higher in the group with than
14
15
16 without an increased CAVI, although it did not reach a statistical significance (Table 3).
17
18
19

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

DISCUSSION

The CAVI reflects the stiffness of the whole arterial segment composed of the aorta, femoral artery, and tibial artery, which is not affected by BP at the time of measurement.^{8-11,13,14} Thus, the CAVI can be used to compare the degree of arteriosclerosis. The CAVI is reported to increase in the elderly and in patients with hypertension, DM, dyslipidemia, and CVD.⁸⁻¹¹ In the present study, it was also confirmed that the CAVI at baseline was higher in patients with hypertension, DM, dyslipidemia, and CVD, as described in previous studies.⁸⁻¹¹ Moreover, the CAVI at baseline was significantly correlated with age, pulse pressure, and HbA1c. Medical treatment regimens for hypertension, DM, and dyslipidemia did not change within 6 months after ADT administration, although drugs, such as statins and angiotensin II receptor blockers, were reported to be able to improve the CAVI.⁸ Thus, medical treatment regimens for hypertension, DM, and dyslipidemia were not thought to affect the change in the CAVI of patients who received ADT during this short-term study.

This study was the first to assess arterial stiffness induced by ADT in PCa patients using the CAVI. It demonstrated that 32 of 58 (55.2%) patients showed an increase in arterial stiffness at 6 months of follow-up, although the whole cohort did not show a significant increase. Previous studies suggested that patients who received GnRH

1
2
3 agonist monotherapy, such as goserelin or leuprorelin, developed a significant increase
4
5
6 in arterial stiffness within 3 to 6 months after ADT initiation.¹⁵⁻¹⁷ It was not possible to
7
8
9 simply compare the present results with the results of previous studies, because previous
10
11
12 studies included smaller numbers of enrolled patients, patients with different
13
14
15 backgrounds, and different methods to assess arterial stiffness, such as PWV.¹⁵⁻¹⁷ Some
16
17
18 patients actually had a risk of developing arterial stiffness after ADT administration,
19
20
21 although no patients had new-onset cardiovascular events in the present study during
22
23
24 the observation period.
25
26

27
28 Direct vasodilatory effects of testosterone on calcium channels, potassium channels, or
29
30 both of vascular smooth muscle have also been recognized.¹⁶⁻¹⁹ Endogenous
31
32 testosterone may exert a continuous beneficial effect on the vessel wall.¹⁶⁻¹⁷ Therefore,
33
34
35 testosterone suppression under ADT might have an adverse effect on the general
36
37
38 vasculature in PCa patients. However, the whole cohort did not show increased arterial
39
40
41 stiffness, despite complete suppression of testosterone in all patients (Figure 1b). Thus,
42
43
44 we could not explain the pathogenesis of arterial stiffness in patients who received ADT
45
46
47 owing to only the direct effect of testosterone.
48
49
50
51

52
53 So far, many researchers have reported that ADT promotes the development of
54
55
56 metabolic disturbances, particularly insulin resistance and lipid profile changes.^{6,7,15-17}
57
58
59
60
61
62
63
64
65

1
2
3 The relationship between ADT and insulin resistance appears to be a continuum, with
4
5
6 short-term therapy leading to reduced insulin sensitivity and long-term ADT resulting in
7
8
9 hyperglycemia, increased risk of metabolic syndrome, and, finally, overt type 2
10
11
12 DM.^{6,20-23} On the other hand, the reported effects of ADT on the lipid profile are
13
14
15 variable. TC increased significantly in the first 3 to 12 months of ADT.^{7,16,24}
16
17
18 Triglycerides increased significantly in the first 3 to 12 months of ADT,^{7,25} while
19
20
21 Dockery et al. and Brada-Basaria et al. reported that triglycerides did not increase
22
23
24 significantly after ADT administration.^{16,26} HDL-C increased significantly in the first 3
25
26
27 to 12 months of ADT^{7,16,25}, while Smith et al. reported that HDL-C decreased up to 5%
28
29
30 after 12 months of ADT.²⁷ LDL-C increased significantly in the first 6 to 12 months of
31
32
33 ADT,^{17,25,27,29} while Dockery et al. and Smith et al. reported that LDL-C did not
34
35
36 increase significantly.^{16,27} In the present study, TC, HLD-C, and LDL-C increased
37
38
39 significantly at 1 month after the start of ADT and sustained high values afterwards.
40
41
42
43 Additionally, the patients were divided into two groups according to whether they were
44
45
46 taking lipid-lowering drugs. Subsequently, lipid profile changes were compared in each
47
48
49 group between baseline and 1 month, 3 months, and 6 months of follow-up. In both
50
51
52 groups, TC, HDL-C, and LDL-C increased significantly at 1 month of follow-up and
53
54
55 sustained high values thereafter (data not shown). If serum levels of LDL-C or
56
57
58
59
60
61
62
63
64
65

1
2
3 LDL-C/HDL-C worsen in patients during ADT, clinicians should consider a medical
4
5
6 treatment regimen for dyslipidemia.
7
8

9 Table 2 shows that HDL-C and LDL-C increased significantly at 6 months of
10
11 follow-up in the groups with and without increased the CAVI. Table 3 shows univariate
12
13 analyses of the clinical variables at baseline for increased arterial stiffness after ADT
14
15
16 administration. At baseline, HDL-C was lower and LDL-C and LDL-C/HDL-C were
17
18
19 higher in the group with than without an increased arterial stiffness after ADT
20
21
22 administration. Although both ‘good cholesterol’ HDL-C and ‘bad cholesterol’ LDL-C
23
24
25 increased at 6 months of follow-up, the present study suggested that the balance
26
27
28 between HDL-C and HDL-C, or LDL-C/HDL-C, might have an impact on the
29
30
31 development of arterial stiffness after ADT administration. LDL-C/HDL-C is a routine
32
33
34 variable that should be readily available to clinicians.¹² Thus, clinicians might be able to
35
36
37 monitor PCa patients who have a high risk of development of arterial stiffness after
38
39
40 ADT administration by referring to baseline LDL-C/HDL-C levels prior to ADT.
41
42
43
44
45
46

47 There are some limitations in the present study. First, the duration of follow-up after
48
49
50 ADT administration was short. Further investigation is necessary to confirm patients’
51
52
53 arterial stiffness with long-term ADT. Second, the sample size was small, although the
54
55
56 number of enrolled patients in this study was larger than in previous studies. Third, it
57
58
59
60
61
62
63
64
65

1
2
3 was not possible to assess the effects of insulin resistance or hyperinsulinemia, because
4
5
6 insulin levels were not measured during the present study. However, in the present study,
7
8
9 no patients were confirmed to have new-onset DM or drug therapy within 6 months of
10
11
12 follow-up. Fourth, this study included three kinds of ADT, such as goserelin or
13
14
15 leuprorelin in combination with bicalutamide, or degarelix. However, the CAVI and
16
17
18 lipid profile changes were not significantly different by the type of ADT (data not
19
20
21 shown).
22
23
24

25 The results of the present study demonstrated that testosterone suppression leads to
26
27 increased arterial stiffness in some patients who received ADT, although patients as a
28
29 whole did not show a significant change with short-term ADT. The present findings
30
31 suggest that higher baseline LDL-C/HDL-C levels may be able to predict patients who
32
33
34
35
36
37 have a high risk of developing arterial stiffness after ADT administration.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments: None.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Suzuki H, Kamiya N, Imamoto T, et al (2008) Current topics and perspectives relating to hormone therapy for prostate cancer. *Int J Clin Oncol* 13:401-410
2. Kamiya N, Suzuki H, Nishimura K, et al (2014) Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. *Jpn J Clin Oncol* 44:263-269
3. Imamoto T, Suzuki H, Utsumi T, et al (2009) Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. *Future Oncol* 5:1005-1013
4. Kamiya N, Suzuki H, Ueda T, et al (2014) Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study. *Int J Clin Oncol* 19:157-164
5. Shahinian VB, Kuo YF, Freeman JL, et al (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. *Cancer* 103:1625-24
6. Allan CA, Collins VR, Frydenberg M, et al (2014) Androgen deprivation therapy complications. *Endocr Relat Cancer* 21:T119-29

- 1
2
3 7. Smith MR, Finkelstein JS, McGovern FJ, et al (2002) Changes in body composition
4
5
6 during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab
7
8
9 87:599-603
10
- 11
12 8. Shirai K, Hiruta N, Song M, et al (2011) Cardio-ankle vascular index (CAVI) as a
13
14 novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler
15
16 Thromb 18:924-938
17
18
19
- 20
21
22 9. Nagayama D, Ohira M, Saiki A, et al (2014) Sarpogrelate hydrochloride decreases
23
24 cardio-ankle vascular index accompanied by increased serum lipidprotein lipase
25
26 mass in type 2 diabetic patients. Int Heart J 55:337-341
27
28
29
- 30
31
32 10. Shirai K, Song M, Suzuki J, et al (2011) Contradictory effects of β 1- and
33
34 α 1-aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI) -
35
36 The independency of CAVI from blood pressure. J Atheroscler Thromb 18:49-55
37
38
39
- 40
41
42 11. Dobsak P, Soska V, Sochor O, et al (2015) Increased Cardio-ankle vascular index in
43
44 hyperlipidemic patients without diabetes or hypertension. J Atheroscler Thromb
45
46 22:272-283
47
48
49
- 50
51
52 12. Mizuno K, Nakaya N, Teramoto T, et al (2012) Usefulness of LDL-C-related
53
54 parameters to predict cardiovascular risk and effect of pravastatin in
55
56 mild-to-moderate hypercholesterolemia. J Atheroscler Thromb 19:176-185
57
58
59
60
61
62
63
64
65

- 1
2
3 13. Hasegawa M, Rodbard S. (1979) Effect of posture on arterial pressure, timing of the
4
5
6 arterial sounds and pulse wave velocities in the extremities. *Cardiology* 64:122-132
7
8
9
10 14. Yamabe T, Yoshizawa M, Saijo Y, et al (2004) Brachio-ankle pulse wave velocity
11
12 and cardio-ankle vascular index (CAVI). *Biomed Pharmacother* 58 Suppl1:S95-98
13
14
15
16 15. Smith JC, Bennett S, Evans LM, et al (2001) The effects of induced hypogonadism
17
18 on arterial stiffness, body composition, and metabolic parameters in males with
19
20
21
22 prostate cancer. *J Clin Endocrinol Metab* 86:4261-4267
23
24
25
26 16. Dockery F, Bulpitt CJ, Agarwal S, et al (2003) Testosterone suppression in men with
27
28 prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. *Clin*
29
30
31
32 *Sci (Lond)* 104:195-201
33
34
35 17. Dockery F, Bulpitt CJ, Agarwal S, et al (2009) Effects of androgen suppression
36
37
38 compared with androgen receptor blockade on arterial stiffness in men with prostate
39
40
41
42 cancer. *J Androl* 30:410-415
43
44
45 18. Deenadayalu VP, White RE, Stallone JN, et al (2001) Testosterone relaxes coronary
46
47
48 arteries by opening the large-conductance, calcium-activated potassium channel. *Am*
49
50
51
52 *J Physiol Heart Circ Physiol* 281:H1720-1727
53
54
55 19. Jones RD, English KM, Pugh PJ, et al (2002) Pulmonary vasodilatory action of
56
57
58
59
60
61
62
63
64
65 testosterone: evidence of a calcium antagonistic action. *J Cardiovasc Pharmacol*

1
2
3 39:814-823
4
5

6 20. Shahani S, Braga-Basaria M, Basaria S. (2008) Androgen deprivation therapy in
7
8 prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab
9
10
11
12 93:2042-2049
13

14
15 21. Sağlam, HS, Köse O, Kumsar S, et al (2012) Fasting blood glucose and lipid profile
16
17 alterations following twelve-month androgen deprivation therapy in men with
18
19 prostate cancer. Scientific World Journal 2012:696329
20
21
22

23
24
25 22. McGrowder DA, Jackson LA, Crawford TV. (2012) Prostate cancer and metabolic
26
27 syndrome: is there a link? Asian Pac J Cancer Prev 13:1-13
28
29

30
31 23. Mohamedali HZ, Breunis H, Timilshina N, et al (2011) Changes in blood glucose
32
33 and cholesterol levels due to androgen deprivation therapy in men with
34
35 non-metastatic prostate cancer. Can Urol Assoc J 5:28-32
36
37
38

39
40
41 24. Saylor PJ, Smith MR. (2009) Metabolic complications of androgen deprivation
42
43 therapy for prostate cancer. J Urol 181:1998-2008
44
45

46
47 25. Morote J, Gómez-Caamaño A, Alvarez-Ossorio JL, et al (2015) The metabolic
48
49 syndrome and its components in patients with prostate cancer on androgen
50
51 deprivation therapy. J Urol 193:1963-1969
52
53
54

55
56
57 26. Braga-Basaria M, Muller DC, Carducci MA, et al (2006) Lipoprotein profile in men
58
59
60
61
62
63
64
65

1
2
3 with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res
4
5
6 18:494-498
7

8
9 27. Smith MR, Malkowicz SB, Chu F, et al (2008) Toremifene improves lipid profiles in
10
11 men receiving androgen-deprivation therapy for prostate cancer: interim analysis of
12
13 a multicenter phase III study. J Clin Oncol 26:1824-1829
14
15
16

17
18 28. Torimoto K, Samma S, Kagebayashi Y, et al (2011) The effects of androgen
19
20 deprivation therapy on lipid metabolism and body composition in Japanese patients
21
22
23 with prostate cancer. Jpn J Clin Oncol 41:577-581
24
25
26

27
28 29. Salvador C, Planas J, Agreda F, et al (2013) Analysis of the lipid profile and
29
30 atherogenic risk during androgen deprivation therapy in prostate cancer patients.
31
32
33 Urol Int 90:41-4
34
35
36

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 **Figure captions**
3

4
5 **Fig. 1. Comparisons of clinical laboratory variables between baseline and after 1**
6
7
8 **month, 3 months, and 6 months of follow-up**
9

10
11
12
13
14
15 Androgen deprivation therapy significantly lowers PSA and testosterone. After 1 month
16
17
18 of follow-up, TC, HDL-C, and LDL-C are significantly increased, while the other
19
20
21 clinical laboratory variables do not show significant changes.
22

23
24
25 *, $P < 0.001$
26

27
28 PSA, prostate-specific antigen; eGFR, estimated glomerular filtration rate; TC, total
29
30 cholesterol; HDL-C, high density-lipoprotein cholesterol; LDL-C, low
31
32 density-lipoprotein cholesterol; CRP, C-reactive protein; d-ROMs, diacron-reactive
33
34 oxygen metabolites; CAVI, cardio-ankle vascular index.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Demographic and baseline characteristics of the study patients

Age, years	71.8 (\pm 7.1)
BMI, kg/m ²	23.4 (\pm 2.9)
Systolic blood pressure, mmHg	133.7 (\pm 16.9)
Diastolic blood pressure, mmHg	77.6 (\pm 11.0)
Pulse pressure	56.3 (\pm 15.6)
Comorbidities	
Hypertension, n (%)	27 (46.6)
Diabetes mellitus, n (%)	16 (27.6)
Dyslipidemia, n (%)	20 (34.5)
Cardiovascular disease, n (%)	9 (15.5)
PSA, ng/mL	137.0 (\pm 475.8)
Testosterone, ng/mL	4.2 (\pm 2.0)
HbA1c, %	5.9 (\pm 0.9)
TNM classification at diagnosis, n (%)	
T1-2 N0 M0	32 (55.2)
T3-4 N0 M0	16 (27.6)
T1-4 N1 M0	1 (1.7)

T1-4 N1 M1	9 (15.5)
No. Gleason score at diagnosis, n (%)	
6 or less	3 (5.2)
7	33 (56.9)
8-10	22 (37.9)
Treatment	
ADT alone	35 (60.4)
Before radiotherapy	18 (31.0)
Biochemical recurrence after RP	5 (8.6)

BMI, body mass index; PSA, prostate specific antigen; ADT, androgen deprivation therapy.

Table 2. Comparison of clinical laboratory values between baseline and 6 months**of follow-up**

Variable	Increased CAVI (n=32)			Not-increased CAVI (n=26)		
	Baseline	6 months	<i>P</i> value	Baseline	6 months	<i>P</i> value
eGFR, mL/min/1.73 m ₂	67.0 (±13.9)	67.1 (±14.2)	0.925	67.7 (±15.0)	66.5 (±15.4)	0.512
Triglyceride, mg/dL	152.0 (±67.8)	154.8 (±77.7)	0.955	142.4 (±89.2)	143.3 (±110.3)	0.879
Total cholesterol, mg/dL	189.8 (±38.1)	209.6 (±36.2)	<0.001	180.3 (±28.2)	207.7 (±26.6)	<0.001
HDL-C, mg/dL	49.7 (±9.1)	53.8 (±10.3)	0.008	53.2 (±13.5)	60.9 (±15.3)	0.002
LDL-C, mg/dL	113.9 (±35.1)	126.5 (±37.5)	<0.001	100.9 (±24.8)	117.3 (±26.4)	<0.001
LDL-C/HDL-C	2.4 (±0.9)	2.5 (±0.9)	0.188	2.0 (±0.7)	2.1 (±0.8)	0.451
CRP, mg/dL	0.16 (±0.34)	0.64 (±3.30)	0.672	0.10 (±0.18)	0.06 (±0.07)	0.400
d-ROMs, U.CARR	350.1 (±56.5)	368.3 (±78.0)	0.110	329.0 (±71.9)	335.0 (±75.7)	0.841

CAVI, cardio-ankle vascular index; eGFR, estimated glomerular filtration rate; HDL-C,

high density-lipoprotein cholesterol; LDL-C, low density-lipoprotein cholesterol; CRP,

C-reactive protein; d-ROMs, diacron-reactive oxygen metabolites.

Table 3. Univariate analyses of the clinical variables at baseline for increased arterial stiffness after androgen deprivation therapy

Variables	Increased CAVI (n=32)	Not-increased CAVI (n=26)	<i>P</i> value
Age, years	70.7 (±7.6)	73.2 (±6.4)	0.183
BMI, kg/m ²	23.2 (±2.5)	23.8 (±3.3)	0.474
Systolic blood pressure, mmHg	134.6 (±17.5)	132.7 (±16.5)	0.685
Diastolic blood pressure, mmHg	77.3 (±10.7)	77.8 (±11.6)	0.865
Pulse pressure	57.2 (±16.7)	54.9 (±14.2)	0.814
Comorbidities			
Hypertension, n (%)	17 (53.1)	18 (69.2)	0.212
Diabetes mellitus, n (%)	10 (31.3)	7 (26.9)	0.719
Dyslipidemia, n (%)	19 (59.4)	16 (61.5)	0.867
Cardiovascular disease, n (%)	5 (15.6)	4 (15.4)	0.635
Clinical laboratory values			
PSA, ng/ml	212.2 (±627.6)	44.4 (±106.8)	0.260
TST, ng/ml	4.5 (±2.2)	3.9 (±1.7)	0.453
HbA1c, %	5.9 (±0.9)	6.0 (±0.9)	0.856
eGFR, ml/min/1.73m ²	67.0 (±13.9)	67.7 (±15.0)	0.919
Triglyceride, mg/dl	152.0 (±67.8)	142.4 (±89.2)	0.288

Total cholesterol, mg/dl	189.8 (±38.0)	180.3 (±28.2)	0.298
HDL-C, mg/dl	49.7 (±9.1)	53.2 (±13.5)	0.250
LDL-C, mg/dl	113.9 (±35.1)	100.9 (±24.8)	0.115
LDL-C/HDL-C	2.4 (±0.9)	2.0 (±0.7)	0.083
CRP, mg/dl	0.16 (±0.34)	0.10 (±0.18)	0.249
d-ROMs, U.CARR	350.1 (±56.5)	329.0 (±71.9)	0.222

CAVI, cardio-ankle vascular index; BMI, body mass index; PSA, prostate specific antigen; eGFR, estimated glomerular filtration rate; HDL-C, high density-lipoprotein cholesterol; LDL-C, low density-lipoprotein cholesterol; CRP, C-reactive protein; d-ROMs, diacron-reactive oxygen metabolites.



